4.5 Article

The epidemiology of alcohol use disorders cross-nationally: Findings from the World Mental Health Surveys

期刊

ADDICTIVE BEHAVIORS
卷 102, 期 -, 页码 -

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.addbeh.2019.106128

关键词

Alcohol; Abuse; Dependence; Remission; Comorbidity; Prevalence

资金

  1. United States National Institute of Mental Health (NIMH) [R01 MH070884]
  2. John D. and Catherine T. MacArthur Foundation
  3. Pfizer Foundation
  4. United States Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  5. Fogarty International Center [FIRCA R03-TW006481]
  6. Pan American Health Organization
  7. Eli Lilly and Company
  8. Ortho-McNeil Pharmaceutical Inc.
  9. GlaxoSmithKline
  10. Bristol-Myers Squibb
  11. Australian National Health and Medical Research Council (NHMRC) [APP1081984]
  12. Australian Government Department of Health and Ageing
  13. Argentinian Ministry of Health (Ministerio de Salud de la Nacion)
  14. State of Sao Paulo Research Foundation (FAPESP) [03/00204-3]
  15. Ministry of Health
  16. National Center for Public Health Protection
  17. Ministry of Social Protection
  18. Center for Excellence on Research in Mental Health (CES University)
  19. Secretary of Health of Medellin
  20. European Commission [QLG5-1999-01042, SANCO 2004123, EAHC 20081308]
  21. Piedmont Region (Italy)
  22. Fondo de Investigation Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028]
  23. Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
  24. Departament de Salut, Generalitat de Catalunya, Spain
  25. DIUE de la Generalitat de Catalunya [2017 SGR 452, 2014 SGR 748]
  26. Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
  27. Japanese Fund through United Nations Development Group Iraq Trust Fund (UNDG ITF)
  28. European Fund through United Nations Development Group Iraq Trust Fund (UNDG ITF)
  29. Israel National Institute for Health Policy and Health Services Research
  30. National Insurance Institute of Israel
  31. Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour and Welfare [H13SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006]
  32. Lebanese Ministry of Public Health
  33. WHO (Lebanon)
  34. National Institute of Health/Fogarty International Center [R03 TW006481-01]
  35. Algorithm
  36. AstraZeneca
  37. Benta
  38. Bella Pharma
  39. Eli Lilly
  40. Glaxo Smith Kline
  41. Lundbeck
  42. Novartis
  43. OmniPharma
  44. Pfizer
  45. Phenicia
  46. Servier
  47. UPO
  48. National Institute of Psychiatry Ramon de la Fuente [INPRFM-DIES -19 -4280]
  49. National Council on Science and Technology [CONACyT-G30544-H]
  50. Pan American Health Organization (PAHO)
  51. New Zealand Ministry of Health
  52. Alcohol Advisory Council
  53. Health Research Council
  54. WHO (Geneva)
  55. WHO (Nigeria)
  56. Federal Ministry of Health, Abuja, Nigeria
  57. Health & Social Care Research & Development Division of the Public Health Agency
  58. National Institute of Health of the Ministry of Health of Peru
  59. Iceland from the EEA Financial Mechanism [PL 0256]
  60. Liechtenstein from the EEA Financial Mechanism [PL 0256]
  61. Norway from the EEA Financial Mechanism [PL 0256]
  62. Norwegian Financial Mechanism
  63. Polish Ministry of Health
  64. Champalimaud Foundation
  65. Gulbenkian Foundation
  66. Foundation for Science and Technology (FCT)
  67. US National Institute of Mental Health [R01-MH059575, RO1-MH61905]
  68. National Institute of Drug Abuse
  69. South African Department of Health
  70. University of Michigan
  71. Regional Health Authorities of Murcia (Servicio Murciano de Salud)
  72. Regional Health Authorities of Murcia (Consejeria de Sanidad y Politica Social)
  73. Fundacion para la Formacion e Investigacion Sanitarias (FFIS) of Murcia
  74. National Institute of Mental Health (NIMH) [U01-MH60220]
  75. National Institute of Drug Abuse (NIDA)
  76. Substance Abuse and Mental Health Services Administration (SAMHSA)
  77. Robert Wood Johnson Foundation (RWJF) [044708]
  78. John W. Alden Trust
  79. NHMRC [1135991]
  80. NIDA NIH grant [R01 DA044170-02]
  81. Danish National Research Foundation (Niels Bohr Professorship)
  82. John Cade Fellowship from National Health and Medical Research Council [APP1056929]

向作者/读者索取更多资源

Background: Prevalences of Alcohol Use Disorders (AUDs) and Mental Health Disorders (MHDs) in many individual countries have been reported but there are few cross-national studies. The WHO World Mental Health (WMH) Survey Initiative standardizes methodological factors facilitating comparison of the prevalences and associated factors of AUDs in a large number of countries to identify differences and commonalities. Methods: Lifetime and 12-month prevalence estimates of DSM-IV AUDs, MHDs, and associations were assessed in the 29 WMH surveys using the WHO CIDI 3.0. Results: Prevalence estimates of alcohol use and AUD across countries and WHO regions varied widely. Mean lifetime prevalence of alcohol use in all countries combined was 80%, ranging from 3.8% to 97.1%. Combined average population lifetime and 12-month prevalence of AUDs were 8.6% and 2.2% respectively and 10.7% and 4.4% among non-abstainers. Of individuals with a lifetime AUD, 43.9% had at least one lifetime MHD and 17.9% of respondents with a lifetime MHD had a lifetime AUD. For most comorbidity combinations, the MHD preceded the onset of the AUD. AUD prevalence was much higher for men than women. 15% of all lifetime AUD cases developed before age 18. Higher household income and being older at time of interview, married, and more educated, were associated with a lower risk for lifetime AUD and AUD persistence. Conclusions: Prevalence of alcohol use and AUD is high overall, with large variation worldwide. The WMH surveys corroborate the wide geographic consistency of a number of well-documented clinical and epidemiological findings and patterns.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据